2seventy bio's CAR-T Trial Halted After Pediatric Death

2seventy bio has paused its Phase I CAR T-cell therapy trial for pediatric acute myeloid leukemia after a patient death. The trial was being conducted in partnership with Seattle Children’s, and the company's DARIC technology is used to regulate CAR T-cell responses and enable "on-demand" control of engineered T-cells. The child who died was the first to receive the second dose level of 2seventy..